+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Plasma Fractionation Market

  • ID: 5387801
  • Report
  • June 2021
  • Region: Global
  • 243 pages
  • Qualiket Research
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Baxalta Incorporated
  • Biotest AG
  • CSL Ltd.
  • etc.
  • Grifols S.A
  • Kedrion S.p.A
  • MORE
Plasma fractionation is a definite as process of separating various components of blood plasma which are used for producing different therapeutic plasma products. These plasma products are used for treating different medical conditions. For instance, coagulation factor VIII is a plasma derivative which is primarily used for treatment & prophylaxis of hemophilia. Also, it is also used to prevent excessive blood loss during surgical procedures. Similarly, immunoglobulins are used in the treatment of primary & secondary immune deficiencies.

Market Drivers

The increase in adoption of immunoglobulins in various therapeutic applications is expected to boost the growth of global plasma fractionation market over the forecast period. Thus, the increasing use of immunoglobulin will magnify its dominance & improve market prospects. Immunoglobulins are a glycoprotein molecule which are derived through plasma & act as antibodies. From past few years, diagnosis rate of various immunological diseases has increased due to technological advancements. Also, the rise in genetic research for characterizing & diagnosing immunodeficiency will raise the clinical need for immunoglobulins due to the increase in number of diagnosed patients.

Furthermore, the increase in focus on establishing advanced plasma fractionation facilities by key player. For instance, in 2019, Kedrion Biopharma had announced that the company received approval from U.S. Food and Drug Administration (USFDA) for establishing a plasma manufacturing facility in Melville which would be dedicated to producing plasma patients. The growing establishments of such facilities is expected to drive the global plasma fractionation market growth.

Market Restraints

Stringent regulatory policies may hamper the growth of global plasma fractionation market growth over the forecast period. As plasma products are separated from blood, the product is strictly regulated by regulatory authorities. Stringent rules and regulations pertaining to the manufacturing facility, source of whole blood, isolation process among others can hamper the market growth.

Impact of COVID-19 on Market

Spread of COVID-19 has affected every industry across the globe. For instance, after COVID-19 was declared as a pandemic by the World Health Organization (WHO), countries worldwide announced nationwide lockdowns to observe social distancing as a measure to contain the spread. This leads to disruption, challenges, and changes in each sector of every industry. Also, the global plasma fractionation market was negatively impacted by the pandemic, due to the decrease in number of blood donations and plasma collections.

Market Segmentation

The Global Plasma Fractionation Market is segmented into product such as Albumin, Immunoglobulins, Coagulation factor VIII, Coagulation factor IX. In terms of market share, by product, immunoglobulin is the largest segment in the global plasma fractionation market which expected to exhibit the fastest growth rate during the forecast period. Further, market is segmented into sector such as Public Sector, and Private sector.

Regional Analysis

The Global Plasma Fractionation Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

The North America is expected to hold the largest market share for plasma fractionation market followed by Europe. The large share of North America region in the global market is attributed to the increase in use of immunoglobulins in various therapeutic areas, the rise in geriatric population, and the growing prevalence of respiratory diseases and AATD. For instance, as per the Alzheimer's Association stated that around 5.8 million people in U.S. are suffering from Alzheimer’s disease in 2018. Alzheimer's Disease is a 6th leading cause of death in the U.S. and is more prevalent among people above 65 years of age, as around 5.6 million patients fall in this age bracket.

Key Players

The Global Plasma Fractionation Market is consolidated with key players such as Grifols S.A, Octapharma AG, CSL Ltd., Baxalta Incorporated, Kedrion S.p.A, Takeda Pharmaceutical Company Ltd, Sanquin, Biotest AG, etc.

Market Taxonomy

By Product
  • Albumin
  • Immunoglobulins
  • Coagulation factor VIII
  • Coagulation factor IX
By Sector
  • Public Sector
  • Private Sector
By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Key Questions Addressed by the Report
  • What are the Key Opportunities in Global Plasma Fractionation Market?
  • What will be the growth rate from 2019 to 2027?
  • Which segment/region will have highest growth?
  • What are the factors that will impact/drive the Market?
  • What is the competitive Landscape in the Industry?
  • What is the role of key players in the value chain?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Baxalta Incorporated
  • Biotest AG
  • CSL Ltd.
  • etc.
  • Grifols S.A
  • Kedrion S.p.A
  • MORE
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope

2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources

3 Executive Summary

4 Global Plasma Fractionation Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 Global Plasma Fractionation Market, By Product
5.1 Y-o-Y Growth Comparison, By Product
5.2 Global Plasma Fractionation Market Share Analysis, By Product
5.3 Global Plasma Fractionation Market Size and Forecast, By Product
5.3.1 Albumin
5.3.2 Immunoglobulins
5.3.3. Coagulation factor VIII
5.3.4 Coagulation factor IX

6 Global Plasma Fractionation Market, By Sector
6.1 Y-o-Y Growth Comparison, By Sector
6.2 Global Plasma Fractionation Market Share Analysis, By Sector
6.3 Global Plasma Fractionation Market Size and Forecast, By Sector
6.3.1 Public Sector
6.3.2 Private Sector

7 Global Plasma Fractionation Market, By Region
7.1 Global Plasma Fractionation Market Share Analysis, By Region
7.2 Global Plasma Fractionation Market Share Analysis, By Region
7.3 Global Plasma Fractionation Market Size and Forecast, By Region

8 North America Plasma Fractionation Market Analysis and Forecast (2020 – 2027)
8.1 Introduction
8.2 North America Plasma Fractionation Market Share Analysis, By Product
8.3 North America Plasma Fractionation Market Size and Forecast, By Sector
8.4 North America Plasma Fractionation Market Size and Forecast, By Country
8.4.1 U.S.
8.4.2 Canada
8.4.3 Mexico

9 Europe Plasma Fractionation Market Analysis and Forecast (2020 – 2027)
9.1 Introduction
9.2 Europe Plasma Fractionation Market Share Analysis, By Product
9.3 Europe Plasma Fractionation Market Size and Forecast, By Sector
9.4 Europe Plasma Fractionation Market Size and Forecast, By Country
9.4.1 Germany
9.4.2 France
9.4.3 UK
9.4.4. Rest of Europe

10 Asia Pacific Plasma Fractionation Market Analysis and Forecast (2020 – 2027)
10.1 Introduction
10.2 Asia Pacific Plasma Fractionation Market Share Analysis, By Product
10.3 Asia Pacific Plasma Fractionation Market Size and Forecast, By Sector
10.4 Asia Pacific Plasma Fractionation Market Size and Forecast, By Country
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific

11 Latin America Plasma Fractionation Market Analysis and Forecast (2020 – 2027)
11.1 Introduction
11.2 Latin America Plasma Fractionation Market Share Analysis, By Product
11.3 Latin America Plasma Fractionation Market Size and Forecast, By Sector
11.4 Latin America Plasma Fractionation Market Size and Forecast, By Country

12 Middle East Plasma Fractionation Market Analysis and Forecast (2020 – 2027)
12.1 Introduction
12.2 Middle East Plasma Fractionation Market Share Analysis, By Product
12.3 Middle East Plasma Fractionation Market Size and Forecast, By Sector
12.4 Middle East Plasma Fractionation Market Size and Forecast, By Country

13 Competitive Analysis
13.1 Competition Dashboard
13.2 Market share Analysis of Top Vendors
13.3 Key Development Strategies

14 Company Profiles
14.1 Grifols S.A
14.1.1 Overview
14.1.2 Offerings
14.1.3 Key Financials
14.1.4 Business Segment & Geographic Overview
14.1.5 Key Market Developments
14.1.6 Key Strategies
14.2 Octapharma AG
14.2.1 Overview
14.2.2 Offerings
14.2.3 Key Financials
14.2.4 Business Segment & Geographic Overview
14.2.5 Key Market Developments
14.2.6 Key Strategies
14.3 CSL Ltd
14.3.1 Overview
14.3.2 Offerings
14.3.3 Key Financials
14.3.4 Business Segment & Geographic Overview
14.3.5 Key Market Developments
14.3.6 Key Strategies
14.4 Baxalta Incorporated
14.4.1 Overview
14.4.2 Offerings
14.4.3 Key Financials
14.4.4 Business Segment & Geographic Overview
14.4.5 Key Market Developments
14.4.6 Key Strategies
14.5 Kedrion S.p.A
14.5.1 Overview
14.5.2 Offerings
14.5.3 Key Financials
14.5.4 Business Segment & Geographic Overview
14.5.5 Key Market Developments
14.5.6 Key Strategies
14.6 Takeda Pharmaceutical Company Ltd
14.6.1 Overview
14.6.2 Offerings
14.6.3 Key Financials
14.6.4 Business Segment & Geographic Overview
14.6.5 Key Market Developments
14.6.6 Key Strategies
14.7 Sanquin
14.7.1 Overview
14.7.2 Offerings
14.7.3 Key Financials
14.7.4 Business Segment & Geographic Overview
14.7.5 Key Market Developments
14.7.6 Key Strategies
14.8 Biotest AG
14.8.1 Overview
14.8.2 Offerings
14.8.3 Key Financials
14.8.4 Business Segment & Geographic Overview
14.8.5 Key Market Developments
14.8.6 Key Strategies
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Grifols S.A
  • CSL Ltd.
  • Octapharma AG
  • Baxalta Incorporated
  • Takeda Pharmaceutical Company Ltd
  • Kedrion S.p.A
  • Sanquin
  • Biotest AG
  • etc.
Note: Product cover images may vary from those shown
Adroll
adroll